Increasing pregnancy-related use of prescribed opioid analgesics

Annals of Epidemiology

Volumn 23, Issue 8, 2013, Pages 498-503

  Epstein, Richard A ^a   Bobo, William V ^b   Martin, Peter R ^a   Morrow, James A ^a   Wang, Wei ^a   Chandrasekhar, Rameela ^a   Cooper, William O ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Opioids; Pregnancy; Prescription

Indexed keywords

OPIATE;

ADULT; ARTICLE; COHORT ANALYSIS; DEATH CERTIFICATE; DRUG USE; FEMALE; FETUS DEATH; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

OPIOIDS; PREGNANCY; PRESCRIPTION;

ADULT; ANALGESICS, OPIOID; CONFIDENCE INTERVALS; FEMALE; HUMANS; MEDICAID; MEDICAL RECORDS; POISSON DISTRIBUTION; PREGNANCY; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; TENNESSEE; UNITED STATES; YOUNG ADULT;

EID: 84880710422     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2013.05.017     Document Type: Article

References (66)

1. Zerzan J.T., Morden N.E., Soumerai S., Ross-Degnan D., Roughead E., Zhang F., et al. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Med Care 2006, 44(11):1005-1010.
2. Curtis L.H., Stoddard J., Radeva J.I., Hutchison S., Dans P.E., Wright A., et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006, 41(3 Pt 1):837-855.
3. Becker W.C., Sullivan L.E., Tetrault J.M., Desai R.A., Fiellin D.A. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend 2008, 94(1-3):38-47.
4. Birnbaum H.G., White A.G., Reynolds J.L., Greenberg P.E., Zhang M., Vallow S., et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006, 22(8):667-676.
5. Boudreau D., Von Korff M., Rutter C.M., Saunders K., Ray G.T., Sullivan M.D., et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009, 18(12):1166-1175.
6. Braden J.B., Fan M.Y., Edlund M.J., Martin B.C., DeVries A., Sullivan M.D. Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study. JPain 2008, 9(11):1026-1035.
7. Braden J.B., Sullivan M.D., Ray G.T., Saunders K., Merrill J., Silverberg M.J., et al. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. Gen Hosp Psychiatry 2009, 31(6):564-570.
8. Caudill-Slosberg M.A., Schwartz L.M., Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004, 109(3):514-519.
9. Dunn K.M., Saunders K.W., Rutter C.M., Banta-Green C.J., Merrill J.O., Sullivan M.D., et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010, 152(2):85-92.
10. Gilson A.M., Ryan K.M., Joranson D.E., Dahl J.L. Areassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. JPain Symptom Manage 2004, 28(2):176-188.
11. Hudson T.J., Edlund M.J., Steffick D.E., Tripathi S.P., Sullivan M.D. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. JPain Symptom Manage 2008, 36(3):280-288.
12. Olsen Y., Daumit G.L., Ford D.E. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. JPain 2006, 7(4):225-235.
13. Smith M.Y., Woody G. Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options. Curr Psychiatry Rep 2005, 7(5):337-343.
14. Sullivan M.D., Edlund M.J., Fan M.Y., Devries A., Brennan Braden J., Martin B.C. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008, 138(2):440-449.
15. Cicero T.J., Surratt H., Inciardi J.A., Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007, 16(8):827-840.
16. Dolphine [package insert] 2006, Roxane Laboratories, Inc., Columbus (OH).
17. Oxycontin [package insert] 2010, Purdue Pharma LP, Stamford (CT).
18. Opioid abuse, dependence, and addiction in pregnancy: committee opinion #254. Obstet Gynecol 2012, 119:1070-1076. American College of Obstetricians and Gynecologists and American Society of Addiction Medicine.
19. American Academy of Pain Medicine. Use of opioids for the treatment of chronic pain: a statement from the American Academy of Pain Medicine. American Academy of Pain Medicine 2013 (February).
20. Zagon I.S., Tobias S.W., Hytrek S.D., McLaughlin P.J. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav 1998, 59(1):201-207.
21. Zagon I.S., Verderame M.F., Allen S.S., McLaughlin P.J. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met(5)]enkephalin. Brain Res 1999, 849(1-2):147-154.
22. Zagon I.S., Verderame M.F., McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 2002, 38(3):351-376.
23. Zagon I.S., Wu Y., McLaughlin P.J. Opioid growth factor and organ development in rat and human embryos. Brain Res 1999, 839(2):313-322.
24. McLaughlin P.J., Zagon I.S. Body and organ development of young rats maternally exposed to methadone. Biol Neonate 1980, 38(3-4):185-196.
25. McLaughlin P.J. Exposure to the opioid antagonist naltrexone throughout gestation alters postnatal heart development. Biol Neonate 2002, 82(3):207-216.
26. McLaughlin P.J., Wylie J.D., Bloom G., Griffith J.W., Zagon I.S. Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy: maternal and preweaning effects. Pharmacol Biochem Behav 2002, 71(1-2):171-181.
27. Broussard C.S., Rasmussen S.A., Reefhuis J., Friedman J.M., Jann M.W., Riehle-Colarusso T., et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011, 204(4):314.e1-314.e11.
28. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEngl J Med 2010, 363:2320-2331.
29. Jones H.E., Martin P.R., Heil S.H., Kaltenbach K., Selby P., Coyle M.G., et al. Treatment of opioid-dependent pregnant women: clinical and research issues. JSubst Abuse Treat 2008, 35(3):245-259.
30. Martin P.R., Arria A.M., Fischer G., Kaltenbach K., Heil S.H., Stine S.M., et al. Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict 2009, 18(2):148-156.
31. Stine S.M., Heil S.H., Kaltenbach K., Martin P.R., Coyle M.G., Fischer G., et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse 2009, 35(6):429-433.
32. Unger A.S., Martin P.R., Kaltenbach K., Stine S.M., Heil S.H., Jones H.E., et al. Clinical characteristics of central European and North American samples of pregnant women screened for opioid agonist treatment. Eur Addict Res 2010, 16(2):99-107.
33. Heil S.H., Jones H.E., Arria A., Kaltenbach K., Coyle M., Fischer G., et al. Unintended pregnancy in opioid-abusing women. JSubst Abuse Treat 2011, 40(2):199-202.
34. Creanga A.A., Sabel J.C., Ko J.Y., Wasserman C.R., Shaprio-Mendoza C.K., Taylor P., et al. Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol 2012, 119(5):924-933.
35. Burns L., Mattick R.P. Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug Alcohol Rev 2007, 26(5):487-492.
36. Piper J.M., Mitchel E.F., Snowden M., Hall C., Adams M., Taylor P. Validation of 1989 Tennessee birth certificates using maternal and newborn hospital records. Am J Epidemiol 1993, 137:758-768.
37. Cooper W.O., Ray W.A., Griffin M.R. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstet Gynecol 2002, 100:101-106.
38. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. NEngl J Med 2006, 354:2443-2451.
39. Ray W.A., Griffin M.R. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989, 129:837-849.
40. West S.L., Savitz D.A., Koch G., Strom B.L., Guess H.A., Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995, 142:1103-1112.
41. Ray W.A. Population-based studies of adverse drug effects. NEngl J Med 2003, 349(17):1592-1594.
42. Piper J.M., Mitchel E.F., Ray W.A. Expanded Medicaid coverage for pregnant women to 100 percent of the federal poverty level. Am J Prev Med 1994, 10(2):97-102.
43. Wilcosky T.C., Chambless L.E. Acomparison of direct adjustment and regression adjustment of epidemiologic measures. JChronic Dis 1985, 38:849-856.
44. Dupont W.D. Statistical Modeling for Biomedical Researchers 2009, Cambridge University Press, Cambridge. 2nd ed.
45. R: a language and environment for statistical computing 2012, R Development Core Team, R Foundation for Statistical Computing, Vienna (Austria).
46. Weisner C.M., Campbell C.I., Ray G.T., Saunders K., Merrill J.O., Banta-Green C., et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain 2009, 145(3):287-293.
47. Tamayo-Sarver J.H., Hinze S.W., Cydulka R.K., Baker D.W. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 2003, 93(12):2067-2073.
48. Tamayo-Sarver J.H., Dawson N.V., Hinze S.W., Cydulka R.K., Wigton R.S., Albert J.M., et al. The effect of race/ethnicity and desirable social characteristics on physicians' decisions to prescribe opioid analgesics. Acad Emerg Med 2003, 10(11):1239-1248.
49. Chen I., Kurz J., Pasanen M., Faselis C., Panda M., Staton L.J., et al. Racial differences in opioid use for chronic nonmalignant pain. JGen Intern Med 2005, 20(7):593-598.
50. Morrison R.S., Wallenstein S., Natale D.K., Senzel R.S., Huang L.L. "We don't carry that"-failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. NEngl J Med 2000, 342(14):1023-1026.
51. Luo X., Pietrobon R., Hey L. Patterns and trends in opioid use among individuals with back pain in the United States. Spine (Phila Pa 1976) 2004, 29(8):884-891.
52. Parsells Kelly J., Cook S.F., Kaufman D.W., Anderson T., Rosenberg L., Mitchell A.A. Prevalence and characteristics of opioid use in the US adult population. Pain 2008, 138(3):507-513.
53. Paulozzi L.J., Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf 2008, 17(10):997-1005.
54. Simmons L.A., Havens J.R. Comorbid substance and mental disorders among rural Americans: results from the National Comorbidity Survey. JAffect Disord 2007, 99(1-3):265-271.
55. Havens J.R., Walker R., Leukefeld C.G. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend 2007, 87(1):98-102.
56. Havens J.R., Talbert J.C., Walker R., Leedham C., Leukefeld C.G. Trends in controlled-release oxycodone (OxyContin) prescribing among Medicaid recipients in Kentucky, 1998-2002. JRural Health 2006, 22(3):276-278.
57. Ray W.A., Gigante J., Mitchel E.F., Hickson G.B. Perinatal outcomes following implementation of TennCare. JAMA 1998, 279:314-316.
58. Bowen M.E., Ray W.A., Arbogast P.G., Ding H., Cooper W.O. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008, 198(3):291.e1-291.e5.
59. Cooper W.O., Willy M.E., Pont S.J., Ray W.A. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007, 196:544-545.
60. Bracken M.B. Drug use in pregnancy and congenital heart disease in offspring. NEngl J Med 1986, 314(17):1120.
61. Bracken M.B., Holford T.R. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981, 58(3):336-344.
62. Rothman K.J., Fyler D.C., Goldblatt A., Kreidberg M.B. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979, 109(4):433-439.
63. Shaw G.M., Malcoe L.H., Swan S.H., Cummins S.K., Schulman J. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. Eur J Epidemiol 1992, 8(5):757-760.
64. Shaw G.M., Todoroff K., Velie E.M., Lammer E.J. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998, 57(1):1-7.
65. Zierler S., Rothman K.J. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. NEngl J Med 1985, 313(6):347-352.
66. U.S.Food and Drug Administration FDA works to reduce risk of opioid pain relievers. FDA Consumer Health Information 2012, U.S. Food and Drug Administration, Washington (DC).